

Condensed Consolidated Statement of Cash Flows – Unaudited**For the six months ended 30 June**

	2024	2023
	US\$m	US\$m
Profit before taxation	948.3	1,087.0
Adjustments for:		
Finance costs	292.2	281.7
Depreciation of property, plant and equipment	150.3	169.2
Amortization of other intangible assets	54.2	67.1
Provision for impairment losses, net	14.3	2.0
Write-down of inventories to net realizable value	7.2	11.4
Loss/(gain) on disposal of property, plant and equipment, net	1.0	(0.4)
Employee share-based compensation benefit expenses	0.5	1.0
Share of profits less losses of associated companies and joint ventures	(249.3)	(230.4)
Interest income	(85.9)	(50.4)
(Gain)/loss on changes in fair value of biological assets	(5.7)	3.0
Gain on disposal of an associated company	(3.7)	(4.1)
Others (including unrealized foreign exchange difference)	182.2	(143.1)
	1,305.6	1,194.0
Increase in working capital	(201.4)	(231.0)
Net cash generated from operations	1,104.2	963.0
Interest received	88.6	47.7
Interest paid	(263.1)	(262.4)
Taxes paid	(250.9)	(219.7)
Net cash flows from operating activities	678.8	528.6
Decrease in restricted cash	192.5	15.7
Dividends received from associated companies	154.8	168.7
Dividends received from financial assets at fair value through other comprehensive income	12.5	14.8
Disposal of an associated company	7.7	5.6
Dividend received from a joint venture	5.8	4.3
Disposal of property, plant and equipment	3.2	2.8
Investments in other intangible assets	(403.7)	(390.2)
Payments for purchases of property, plant and equipment	(234.5)	(123.4)
Investments in financial assets at fair value through other comprehensive income	(107.5)	(176.3)
(Increase)/decrease in short-term deposits with original maturity of more than three months	(9.1)	60.3
Investments in associated companies	(6.5)	-
Investments in biological assets	(5.6)	(9.2)
Increased investments in associated companies	(3.5)	-
Increased investment in a joint venture	(1.5)	-
Investment in financial assets at fair value through profit or loss	(0.8)	-
Disposal of assets classified as held for sale	-	16.2
Disposal of a subsidiary company	-	3.3
Disposal of financial assets at fair value through other comprehensive income	-	1.9
Acquisition of a subsidiary company	-	(1.3)
Payments for purchases of investment properties	-	(0.5)
Net cash flows used in investing activities	(396.2)	(407.3)
Proceeds from new bank borrowings and other loans	2,032.0	2,415.9
Capital contributions from non-controlling shareholders	0.9	13.8
Proceeds from issue of shares upon exercise of share options	0.3	-
Repayment of bank borrowings and other loans	(1,697.8)	(2,166.5)
Dividends paid to non-controlling shareholders by subsidiary companies	(209.7)	(160.8)
Increased investments in subsidiary companies	(60.6)	(1.3)
Principal portion of lease payments	(16.1)	(13.9)
Payments for concession fees payable	(12.7)	(12.8)
Payments for purchase of shares under a long-term incentive plan	(1.6)	-
Net cash flows from financing activities	34.7	74.4
Net increase in cash and cash equivalents	317.3	195.7
Cash and cash equivalents at 1 January	2,814.3	2,457.8
Exchange translation	(105.6)	46.5
Cash and cash equivalents at 30 June	3,026.0	2,700.0
Representing		
Cash and cash equivalents and short-term deposits as stated in the condensed consolidated statement of financial position	3,064.8	2,799.6
Less: short-term deposits with original maturity of more than three months	(38.8)	(99.6)
Cash and cash equivalents at 30 June	3,026.0	2,700.0